Lesley G Ellies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6844608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4317-4322.	7.1	454
2	<i>In vivo</i> characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integrative Biology (United Kingdom), 2009, 1, 382-393.	1.3	245
3	Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10042-10047.	7.1	170
4	Real-time <i>In Vivo</i> Molecular Detection of Primary Tumors and Metastases with Ratiometric Activatable Cell-Penetrating Peptides. Cancer Research, 2013, 73, 855-864.	0.9	158
5	Reprogramming the immunological microenvironment through radiation and targeting Axl. Nature Communications, 2016, 7, 13898.	12.8	150
6	Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Research, 2007, 16, 193-201.	2.4	131
7	Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity. Metabolism: Clinical and Experimental, 2016, 65, 1743-1754.	3.4	120
8	Dual Targeting of Integrin αvβ3 and Matrix Metalloproteinase-2 for Optical Imaging of Tumors and Chemotherapeutic Delivery. Molecular Cancer Therapeutics, 2014, 13, 1514-1525.	4.1	92
9	Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene, 2018, 37, 2022-2036.	5.9	70
10	Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models. Nature Communications, 2021, 12, 565.	12.8	51
11	Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. International Journal of Cancer, 2003, 106, 1-7.	5.1	47
12	Multipotent luminal mammary cancer stem cells model tumor heterogeneity. Breast Cancer Research, 2015, 17, 137.	5.0	41
13	Attenuation of TGF-l ² signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Letters, 2014, 346, 129-138.	7.2	39
14	Impact of MMP-2 and MMP-9 enzyme activity on wound healing, tumor growth and RACPP cleavage. PLoS ONE, 2018, 13, e0198464.	2.5	38
15	Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. OncoImmunology, 2017, 6, e1268310.	4.6	11
16	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. Clinical Cancer Research, 2020, 26, 2972-2985.	7.0	9
17	Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. Advanced Science, 2022, 9, .	11.2	9
18	Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studies. Xenobiotica, 2017, 47, 600-606.	1.1	0

#	Article	IF	CITATIONS
19	Collagen and fibronectin: threads linking obesity and breast cancer. Annals of Translational Medicine, 2016, 4, S50-S50.	1.7	0